bromelain concentrate proteolytic enzymes pineapple plant used medicine approved european union debridement removal eschar dead damaged tissue severe burn wounds brand name developed medicine granted orphan drug status european medicines agency contexts bromelain researched possible antiinflammatory effects treating range conditions diseases results studies mixed regarded december anacaulasebcdb nexobrid approved medical use united united states anacaulase gel indicated eschar removal adults deep partial thickness andor full thickness thermal medication approved burns degrees iib ie deep partial skin thickness burns iii ie full thickness burns shown significantly reduce necessity surgical debridement versus standard treatment skin transplants versus randomized controlled concentrate solved sterile gel basis applied onto burn wound covered wound dressing removed four hours healthy surrounding skin protected sterile paraffin ointment ema recommends treatment used hospitals specialised burns bromelain gel contraindicated persons allergic pineapple enzyme common sideeffects fever patients studies local pain wound infections occur frequently standard enzymes nexobrid inhibit liver enzymes ingested involved breaking number drugs including amiodarone chloroquine ibuprofen warfarin known whether mechanism clinical depending surface area depth wound bromelain blood serum concentrations Âµgml expected peak concentrations reached hours terminal halflife varied hours studies data obtained patients comparatively shallow medication extracted stem pineapple plant ananas standardised process lot analysed chemical composition contains mixture proteolytic enzymes main compound stem bromelain bromelain thought active ingredient determined gel basis contains water polyacrylic acid gelling agent disodium hydrogen phosphatesodium hydroxide